These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28905937)

  • 1. SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models.
    Jiang XF; Dai Y; Peng X; Shen YY; Su Y; Wei MM; Liu WR; Ding ZB; Zhang A; Shi YH; Ai J
    Acta Pharmacol Sin; 2018 Feb; 39(2):243-250. PubMed ID: 28905937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
    Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
    Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo.
    Dai MD; Wang YL; Fan J; Dai Y; Ji YC; Sun YM; Peng X; Li LL; Wang YM; Duan WH; Ding J; Ai J
    Acta Pharmacol Sin; 2021 Sep; 42(9):1498-1506. PubMed ID: 33288861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer.
    Taeger J; Moser C; Hellerbrand C; Mycielska ME; Glockzin G; Schlitt HJ; Geissler EK; Stoeltzing O; Lang SA
    Mol Cancer Ther; 2011 Nov; 10(11):2157-67. PubMed ID: 21885862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
    Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
    Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family.
    Brave SR; Ratcliffe K; Wilson Z; James NH; Ashton S; Wainwright A; Kendrew J; Dudley P; Broadbent N; Sproat G; Taylor S; Barnes C; Silva JC; Farnsworth CL; Hennequin L; Ogilvie DJ; Jürgensmeier JM; Shibuya M; Wedge SR; Barry ST
    Mol Cancer Ther; 2011 May; 10(5):861-73. PubMed ID: 21441409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.
    Grünewald S; Politz O; Bender S; Héroult M; Lustig K; Thuss U; Kneip C; Kopitz C; Zopf D; Collin MP; Boemer U; Ince S; Ellinghaus P; Mumberg D; Hess-Stumpp H; Ziegelbauer K
    Int J Cancer; 2019 Sep; 145(5):1346-1357. PubMed ID: 30807645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor.
    Nakanishi Y; Akiyama N; Tsukaguchi T; Fujii T; Sakata K; Sase H; Isobe T; Morikami K; Shindoh H; Mio T; Ebiike H; Taka N; Aoki Y; Ishii N
    Mol Cancer Ther; 2014 Nov; 13(11):2547-58. PubMed ID: 25169980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models.
    Bello E; Colella G; Scarlato V; Oliva P; Berndt A; Valbusa G; Serra SC; D'Incalci M; Cavalletti E; Giavazzi R; Damia G; Camboni G
    Cancer Res; 2011 Feb; 71(4):1396-405. PubMed ID: 21212416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
    Gozgit JM; Wong MJ; Moran L; Wardwell S; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Clackson T; Rivera VM
    Mol Cancer Ther; 2012 Mar; 11(3):690-9. PubMed ID: 22238366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
    Xie L; Su X; Zhang L; Yin X; Tang L; Zhang X; Xu Y; Gao Z; Liu K; Zhou M; Gao B; Shen D; Zhang L; Ji J; Gavine PR; Zhang J; Kilgour E; Zhang X; Ji Q
    Clin Cancer Res; 2013 May; 19(9):2572-83. PubMed ID: 23493349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
    Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
    Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?
    Capdevila J; Carrato A; Tabernero J; Grande E
    Crit Rev Oncol Hematol; 2014 Nov; 92(2):83-106. PubMed ID: 24924525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models.
    Guffanti F; Chilà R; Bello E; Zucchetti M; Zangarini M; Ceriani L; Ferrari M; Lupi M; Jacquet-Bescond A; Burbridge MF; Pierrat MJ; Damia G
    Neoplasia; 2017 Jan; 19(1):35-42. PubMed ID: 27988457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models.
    Zhao G; Li WY; Chen D; Henry JR; Li HY; Chen Z; Zia-Ebrahimi M; Bloem L; Zhai Y; Huss K; Peng SB; McCann DJ
    Mol Cancer Ther; 2011 Nov; 10(11):2200-10. PubMed ID: 21900693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
    Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
    Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
    Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
    Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.